Development of novel benzofuran-isatin conjugates as potential antiproliferative agents with apoptosis inducing mechanism in Colon cancer.

In the current work, a new set of carbohydrazide linked benzofuran-isatin conjugates (5a-e and 7a-i) was designed and synthesised. The anticancer activity for compounds (5b-d, 7a, 7b, 7d and 7g) was measured against NCI-55 human cancer cell lines. Compound 5d was the most efficient, and thus subjected to the five-dose screen where it showed excellent broad activity against almost all tested cancer subpanels. Furthermore, all conjugates (5a-e and 7a-i) showed a good anti-proliferative activity towards colorectal cancer SW-620 and HT-29 cell lines, with an excellent inhibitory effect for compounds 5a and 5d (IC50 = 8.7 and 9.4 µM (5a), and 6.5 and 9.8 µM for (5d), respectively). Both compounds displayed selective cytotoxicity with good safety profile. In addition, both compounds provoked apoptosis in a dose dependent manner in SW-620 cells. Also, they significantly inhibited the anti-apoptotic Bcl2 protein expression and increased the cleaved PARP level that resulted in SW-620 cells apoptosis.

Introduction

Cancer, a large family of diseases, is characterised by fast and uncontrolled cell division and differentiation mechanisms and has the potential to spread to or invade other body parts. For several decades, cancer is considered one of the major world public health problems, and it remains a serious reason of the death of human beings all over the world. Despite the presence of a variety of cancer treatment strategies, the majority of which induces non-selective cell death by targeting the DNA synthesis and/or the replication machinery. These early strategies are accompanied by severe side effects due to the unspecific cytotoxicity towards the cancer cells in addition to the resistance developed against them. Therefore, the development of safe and effective novel anticancer agents with increased selective treatment strategies towards cancer cells has received more attention and still ongoing active search,.

Recent strategies for anticancer development are to target specific biomarkers required for cancer cells division and/or induction of cell apoptosis such as deregulated, mutated, or over expressed proteins and thus, affect cancer cells selectively with minimum influences on normal cells. Among these targets are the anti-apoptotic protein Bcl2 and Poly ADP-ribose polymerase (PARP). In this regard, several reports stated that numerous of cancer cells are characterised by anti-apoptotic proteins (Bcl2) over-expression, which could lead to prevention of cell apoptosis as well as development of drug resistance,. On the other hand, PARP is a family of proteins involved in numerous cellular functions such as DNA repair and genomic stability and also, PARP was reported to activate programmed cell death, through cleavage into PAR (Poly ADP-ribose), which motivates mitochondria to produce apoptosis inducing factors. Thus, the development of compounds that inhibit the antiapoptotic Bcl2 proteins and/or potentiate the cleavage of PARP could be a promising approach to identify new anticancer therapies.

Heterocyclic compounds in particular oxygen containing heterocycles represent an important class of compounds possessing interesting pharmacological and biological activities. Benzofuran nucleus, as a key functional scaffold, represents a basic structure in a diversity of biologically active synthetic and natural products, with broad range of desirable activities including; anti-Alzheimer’s, antibacterial, anti-tubercular, antioxidant, anti-inflammatory, as well as antitumor activities. Benzofuran derivatives exert their antiproliferative activity with diversified mechanisms such as inhibition of tubulin polymerisation,, HIF-1, Aurora B kinase and VEGFR-2 activity. Furthermore, some benzofurans mediate their antiproliferative activity via apoptosis induction in various human cancer cell lines. In addition, benzofuran-based conjugates were largely studied and were found to exert significant anticancer activity, such as conjugation of benzofuran with pyrazole, indole and others,.

On the other hand, isatin is identified as a privileged nucleus that included in many pharmacologically active small molecules, such as antiviral, antimicrobial, anticonvulsant, CNS-acting, as well as anticancer, agents. Over the last few years, hybridisation of isatin nucleus with different heterocycles has been reported as a successful approach to develop efficient antitumor agents towards different cancer types through diverse enzymatic and cellular mechanisms,. To name just a few, isatin-phthalazine (compound I), isatin-thiazolo[3,2-a]benzimidazole (compound II), isatin-thiazolidinone (compound III), isatin-indole (compound IV) and isatin-quinazoline (compound V) conjugates were reported to possess promising anticancer activities (Figure 1).

Figure 1.

Structures of some reported isatin-bearing conjugates (I–V), as well as structures for target benzofuran-isatin conjugates (5a–e and 7a–i).

Encouraged by the aforementioned findings and considering the need to develop safe and effective novel anticancer agents, a new attempt to study the significance of utilisation of heterocycles hybridisation approach to furnish efficient anti-proliferative activity was reported herein. A novel series of benzofuran-isatin conjugates (5a–e and 7a–i, Figure 1) linked by a carbohydrazide group, was designed and synthesised. The new compounds were screened for their potential anticancer activity following NCI, USA protocol against fifty-five different cell lines under nine different cancer panels. In addition, the cytotoxic effect of these conjugates against SW-620 and HT-29 colorectal cancer cell lines was investigated and their ability to induce cell apoptosis was examined. Furthermore, the level of the mitochondrial antiapoptotic protein Bcl2 and the level of cleaved PARP in both SW-620 and HT-29 colorectal cancer cell lines were also determined.

Results and discussion

Chemistry

The adopted synthetic strategy to develop the target N-unsubstituted 3-methyl-N′-(oxoindolin-3-ylidene)benzofuran-2-carbohydrazide derivatives 5a–e was outlined in Scheme 1.

Scheme 1.

Synthesis of target conjugates 5a–e; (i) Anhydrous CH3CN/potassium carbonate/reflux 8 h, (ii) Hydrazine hydrate/methanol/reflux 4 h, (iii) Ethanol/drops glacial acetic acid (Cat.)/reflux 3–6 h.

Key starting ester 3-methylbenzofuran-2-carboxylate 2, was prepared in 85% yield through cyclisation of 1–(2-hydroxyphenyl)ethan-1-one 1 and ethyl bromoacetate in anhydrous acetonitrile with the presence of potassium carbonate. Thereafter, heating of ester derivative 2 with hydrazine hydrate in methanol afforded the corresponding key intermediate 3-methylbenzofuran-2-carbohydrazide 3. Finally, carbohydrazide 3 was condensed with different indoline-2,3-dione derivatives 4a–e, through heating under reflux temperature in absolute ethyl alcohol and few drops of acetic acid, to give the desired benzofuran-based compounds 5a–e, respectively, in 72–89%yield.

On the other hand, Scheme 2 illustrated the synthetic pathway utilised to synthesise N-substituted 3-methyl-N′-(oxoindolin-3-ylidene)benzofuran-2-carbohydrazide derivatives 7a–i. In this scheme, alkylation of indoline-2,3-diones 4a and 4c was accomplished via heating with different alkyl bromide or benzyl bromide derivatives in anhydrous acetonitrile to produce N-substituted indoline-2,3-dione derivatives 6a–i. Then indoline-2,3-diones 6a–i were condensed with the key intermediate carbohydrazide 3 producing target benzofurans 7a–i, respectively, in 75–87% yield.

Scheme 2.

Synthesis of target benzofurans 7a–i; (i) (R-Br or Ar-Br)/Acetonitrile/KI (Cat.)/potassium carbonate/reflux 3 h, (ii) Ethanol absolute/drops glacial acetic acid (Cat.)/reflux 3–6 h.

Structures of the newly prepared benzofuran-based derivatives 5a–e and 7a–i were verified based on spectral and elemental analyses. 1H NMR spectra of 5a–e and 7a–i revealed the presence of two singlet peaks for the protons of C-3 CH3 of benzofuran ring and NH of the hydrazide linker at range δ (2.52–2.72) and (11.37–14.10) ppm, respectively. Moreover, structure of compounds 5a–e was confirmed via presence of another singlet D2O exchangeable signal attributable to the proton of NH for isatin moieties at δ 10.91–11.98 ppm. In addition, 1H NMR spectra of N-benzyl bearing derivatives 7d–f, 7h and 7i displayed the characteristic singlet signal of the benzylic protons at δ 4.98–5.07 ppm, while spectra for hybrids 7a, 7b and 7g revealed the presence of the aliphatic protons corresponding to the N-substituents in these derivatives at δ (3.28 ppm), (0.93, 1.66 and 3.76 ppm) and (0.97, 1.69 and 3.80 ppm), respectively.

On the other hand, 13 C NMR spectra for the novel compounds 5a–e and 7a–i showed one signal belonging to the carbon of CH3 of benzofuran ring at δ 8.12–9.49 ppm, also, they showed two signals belonging to the carbon of C = O functionalities for both the hydrazide linker and isatin moiety at range δ (161.15–163.62) and (164.08–167.02) ppm, respectively. In addition, the existence of benzylic carbon in N-benzyl bearing derivatives 7d–f, 7h and 7i was confirmed by a signal at δ 42.14–46.03 ppm, whereas, the carbons of propyl moiety in compounds 7b and 7g appeared as signals at range δ (11.68–13.00), (20.92–22.98) and (41.30–48.74) ppm.

Biological evaluation

Nci screening of anticancer activity

In the present investigation, the chemical structures for the novel benzofuran-isatin conjugates were presented to the Developmental Therapeutics Program at the National Cancer Institute (NCI), USA. Seven conjugates (5b–d,7a, 7b, 7d and 7g) were selected, according to NCI’s-DTP selection guidelines, for evaluating their potential in vitro anticancer activity against a panel of fifty-five human cancer cell lines representing nine tumour panels according to the NCI, Bethesda, Drug Evaluation Branch protocol,.

Preliminary single high dose screening at 10 μM concentration

Firstly, the seven selected conjugates (5b–d,7a, 7b, 7d and 7g) were screened at a dose of 10 μM for their antiproliferative activity against a panel of fifty-five cancer cell lines. The mean percent growth inhibition values (GI%) for conjugates 5b–d,7a, 7b, 7d and 7g against NCI-55 cancer cell lines were displayed in (Figure 2, Table 1). The primary assay data analysis revealed that the new benzofuran-isatin hybrids showed weak to moderate inhibitory activity some of the subpanel cancer cell lines except for compound 5d that possessed excellent activity against nearly all the cancer cell lines. Although compound 5b, 7a, 7b, 7d and 7g proved inactive against most of the subpanels cancer cell lines with mean GI% = 0.75%, 0.09%, 5.18%, 6.01%, and −0.8%, respectively, they showed selective moderate anticancer activity against certain cell lines such as Ovarian-IGROV1, Non-small cell lung-EKVX, Renal-UO-31 and Breast/MCF7 cancer cell lines with GI% range 17–53% (Table 1).

Figure 2.

Mean % growth inhibition of compounds 5b–d,7a, 7b, 7d and 7g against NCI-55 cancer cell line panel.

Table 1.

In vitro Anticancer screening results of compounds 5b–d,7a, 7b, 7d and 7g against fifty-five human tumour cell lines with single dose assay (10−5 M concentration). Data was provided as cell growth inhibition percentage.

Subpanel / tumour cell lines	Compounda
	5b	5c	5d	7a	7b	7d	7g
Leukaemia
CCRF-CEM	–	–	42.92	–	–	–	–
MOLT-4	–	–	49.14	–	–	–	–
HL-60(TB)	–	21.46	46.13	–	10.94	–	–
K-562	–	18.04	57.50	–	11.45	–	–
SR	–	17.62	56.52	–	–	–	–
RPMI-8226	–	–	NA	NT	NT	–	NT
Non-small cell lung cancer
EKVX	29.63	32.13	62.73	25.07	32.35	30.23	18.10
A549/ATCC	–	27.92	123.59	–	–	–	–
HOP-92	–	26.54	143.99	–	–	12.64	–
HOP-62	–	41.41	124.09	–	18.06	20.82	–
NCI-H322M	–	31.80	69.41	–	11.87	17.83	–
NCI-H23	–	33.05	89.35	–	15.06	13.19	–
NCI-H522	10.36	10.33	45.72	–	10.32	21.72	–
NCI-H460	–	42.60	122.83	–	15.60	24.98	–
Colon cancer
HCC-2998	–	–	56.46	–	–	–	–
COLO 205	–	–	77.24	–	–	–	–
SW-620	–	10.57	64.85	30.57	–	11.21	–
HCT-116	–	32.03	128.55	–	–	–	–
HCT-15	–	–	50.91	–	–	–	–
HT-29	–	–	72.67	–	–	–	–
KM12	–	20.46	56.20	–	–	–	–
CNS cancer
SF-539	–	57.88	62.58	–	–	–	–
SF-268	–	11.66	42.33	–	–	–	–
SF-295	–	20.30	94.95	11.84	11.86	–	–
U251	–	42.58	97.95	–	–	–	–
SNB-19	–	31.48	57.29	–	–	11.60	–
Melanoma
MALME-3M	12.43	64.93	129.46	–	–	–	16.04
LOX IMVI	–	33.82	83.71	–	–	13.84	–
MDA-MB-435	–	–	61.04	–	–	–	–
M14	–	25.40	71.32	–	–	–	–
UACC-257	–	–	49.98	–	–	–	–
UACC-62	10.91	30.94	65.68	–	16.86	20.56	–
SK-MEL-2	–	–	29.13	–	–	–	–
SK-MEL-28	–	–	84.16	–	–	–	–
Ovarian cancer
NCI/ADR-RES	–	29.33	69.51	–	10.33	10.19	–
IGROV1	33.72	44.59	93.67	32.80	42.55	33.59	22.38
OVCAR-3	–	–	165.51	–	–	–	–
OVCAR-8	–	22.46	62.23	–	–	–	–
OVCAR-4	–	31.04	15,285	–	–	–	–
OVCAR-5	–	–	52.33	–	–	–	–
Renal cancer
786-0	–	34.70	166.85	–	–	–	–
CAKI-1	19.50	26.59	151.66	19.44	11.31	18.98	14.14
ACHN	–	35.48	150.93	–	11.60	13.30	–
SN12C	–	29.81	65.13	–	–	–	–
RXF 393	–	11.08	136.15	–	–	–	–
UO-31	26.72	43.42	155.33	–	34.27	33.64	21.86
TK-10	–	–	193.95	–	–	–	–
Prostate cancer
PC-3	–	13.75	78.23	–	10.82	15.73	–
DU-145	–	17.00	82.38	–	–	–	–
Breast cancer
MCF7	19.04	26.66	77.14	28.25	25.04	16.66	13.20
BT-549	–	22.06	29.88	–	–	–	–
MDA-MB-231/ATCC	14.64	29.88	76.19	–	28.99	18.32	–
HS 578 T	–	46.27	74.50	–	–	–	–
MDA-MB-468	–	–	80.10	–	–	–	–
T-47D	–	42.74	139.16	21.80	23.76	33.31	–
Mean inhibition, %	0.75	21.99	87.33	0.09	5.18	6.01	–0.8
Sensitive cell lines no.	9	40	54	7	19	20	6

Only GI % higher than 10% are shown. NT: not tested.

In particular, compound 5d was the most efficient anti-proliferative agent and exhibited excellent activity against almost all subpanel cancer cell lines with mean growth inhibitory activity of 87.33%. Remarkably, compound 5d exerted excellent growth inhibition properties against Non-small cell lung cancer (NCI-H23), CNS cancer (SF-295, U251), Melanoma (LOX IMVI, SK-MEL-28), Ovarian cancer (IGROV1), Prostate cancer (DU-145) and Breast cancer (MDA-MB-468) cell lines with GI% of 89.35, 94.95, 97.95, 83.71, 84.16, 93.67, 82.38 and 80.10%, respectively (Table 1). In addition, conjugate 5d showed good potency with GI% equals or greater than 60% towards Non-small cell lung cancer (EKVX), Colon cancer (COLO 205, HT-29 and SW-620), Melanoma (M14, MDA-MB-435 and UACC-62), Ovarian cancer (OVCAR-8), CNS cancer (SF-539), Renal cancer (SN12C), Breast cancer (MCF7, MDA-MB-231/ATCC and HS 578 T) and Prostate cancer (PC-3) cell lines with GI% of 62.73, 77.24, 72.67, 64.85, 71.32, 61.04, 65.68, 62.23, 62.58, 65.13, 77.14, 76.19, 74.50and 78.23% respectivly (Table 1).

It is worthy to mention that 5d exhibited a lethal cytotoxic impact with GI% >100 against Non-small cell lung cancer (HOP-62, A549/ATCC, HOP-92 and NCI-H460), Colon cancer (HCT-116), Melanoma (MALME-3M), Ovarian cancer (OVCAR-4 and OVCAR-3), Renal cancer (CAKI-1, 786–0, RXF 393, ACHN, TK-10 and UO-31) and Breast cancer (T-47D) cells with GI% values equals 124.09, 123.59, 143.99, 122.83, 128.55, 129.46, 152.85, 165.51, 151.66, 166.85, 136.15, 150.93, 193.95, 155.33 and 139.16%, respectively (Table 1).

On the other hand, compound 5c showed moderate to good activity against some cell lines with mean GI% = 21.99%. The best results of compound 5c was against cancer cell lines Non-small cell lung-HOP-62 (GI% = 41.41%), Non-small cell lung-NCI-H460 (GI% = 42.60%), Renal-UO-31 (GI% = 43.42%), Ovarian-IGROV1 (GI% = 44.59%), Breast-HS-578T (GI% = 46.27%), CNS-SF-539 (GI% = 57.88%) and Melanoma-MALME-3M (GI% = 64.93%) (Table 1).

In vitro 5 dose full NCI-55 cell panel screening.

The preliminary screening results showed that conjugate 5d (NSC: D-819833/1) was the most potent compound in the present study, and displayed effectiveness towards various cell lines represent numerous tumour subpanels (Figure 2). Accordingly, 5d was promoted to the five-dose (0.01–100 µM) screening assay. Accordingly, three main response parameters (GI50, TGI and LC50) towards each of the examined cancer cell line were calculated for hybrid 5d and displayed in Table 2. Where, GI50 values represents molar concentration which produces 50% inhibitory effect in the net cell growth; TGI (cytostatic activity) is the molar concentration with total growth inhibition and LC50 is the cytotoxicity parameter that reflects the molar concentration that results in 50% net cell death. In addition, the mean graph midpoints (MG-MID), representing the GI50 average for the individual subpanels as well as the full panel cell lines were calculated giving an average potency parameter for the examined compound 5d, (Table 3). Furthermore, by dividing the full panel MID by their individual subpanel MID, the selectivity index of compound 5d was calculated and was used to measure the selectivity of 5d towards different cancer cell subpanels.

Table 2.

NCI in vitro screening results (GI50, TGI, and LC50 (μM) of 5d (NSC: D-819833/1) in the five-dose test.

Subpanel /tumour cell lines	Compound 5d
	GI50(µM)	TGI(µM)	LC50(µM)
Leukaemia
CCRF-CEM	NT	>100	>100
HL60(TB)	>100	>100	>100
K-562	NT	>100	>100
MOLT-4	NT	>100	>100
SR	NT	>100	>100
Non-small cell lung cancer
A549/ATCC	NT	NT	NT
EKVX	2.94	>100	>100
HOP-62	1.92	4.02	8.44
HOP-92	1.84	3.98	NT
NCI-H226	2.19	NT	>100
NCI-H23	1.86	4.43	>100
NCI-H322M	NT	NT	>100
NCI-H460	NT	NT	NT
NCI-H522	6.07	>100	>100
Colon cancer
COLO 205	NT	>100	>100
HCC-2998	NT	>100	>100
HCT-116	1.92	NT	NT
HCT-15	NT	>100	>100
HT29	NT	NT	>100
KM12	NT	>100	>100
SW-620	NT	>100	>100
CNS cancer
SF-268	5.18	56.8	>100
SF-295	2.03	4.13	NT
SF-539	1.66	3.16	NT
SNB-19	3.45	16.2	>100
SNB-75	1.25	2.75	6.04
U251	2.03	4.26	NT
Melanoma
LOX IMVI	3.16	>100	>100
MALME-3M	1.81	3.79	NT
M14	NT	>100	>100
MDA-MB-435	NT	>100	>100
SK-MEL-2	2.56	6.62	54.7
SK-MEL-28	NT	NT	NT
SK-MEL-5	NT	NT	>100
UACC-257	NT	>100	>100
UACC-62	5.19	>100	>100
Ovarian cancer
IGROV1	2.10	NT	>100
OVCAR-3	1.84	NT	NT
OVCAR-4	NT	NT	NT
OVCAR-5	NT	NT	>100
OVCAR-8	3.22	>100	>100
NCI/ADR-RES	2.47	NT	>100
SK-OV-3	1.82	3.83	NT
Renal cancer
786-0	1.99	3.84	NT
A498	1.63	4.04	NT
ACHN	1.77	NT	NT
CAKI-1	1.56	3.24	NT
RXF 393	1.79	3.70	NT
SN12C	2.82	>100	>100
TK-10	2.32	4.02	NT
UO-31	NT	NT	NT
Prostate cancer
PC-3	NT	>100	>100
DU-145	NT	NT	>100
Breast cancer
MCF7	NT	>100	>100
MDA-MB-231/ATCC	2.07	5.10	>100
HS 578 T	2.41	7.72	>100
BT-549	5.38	33.7	>100
T-47D	1.70	NT	>100
MDA-MB-468	2.60	6.52	>100

NT: not tested.

Table 3.

Median growth inhibitory concentrationsa (GI50, µM) of in-vitro cancer cell lines subpanel for compound 5d.

Subpanel /tumour cell lines	Compound 5d
	MG-MID	Selectivity index
non-small cell lung cancer	2.80	0.89
Colon Cancer	1.92	1.30
CNS Cancer	2.60	0.96
Melanoma	3.18	0.78
Ovarian Cancer	2.29	1.09
Renal Cancer	1.98	1.26
Breast Cancer	2.83	0.88
Full panel MG-MIDb	2.51

Median value assessed according to the results obtained from NCI’s screening.

GI50 (µM) full panel mean-graph midpoint (MG-MID) = the average sensitivity for all cell lines towards the examined compound.

Results displayed in Table 2, revealed that conjugate 5d exhibited powerful anti-proliferative activity at a single-digit micromolar level towards all the examined human cancer cell subpanels with GI50 values range: 1.25 − 6.07 µM, except for Melanoma HL60(TB) cell line (more than100 µM). Moreover, regarding the cytostatic activity, hybrid 5d exhibited excellent cytostatic activity with TGI values range 2.75–7.72 µM against numerous cell lines including NSCLC (HOP-62, NCI-H23 and HOP-92), CNS Cancer (SF-295, SF-539, SNB-75 and U251), Melanoma (MALME-3Mand SK-MEL-2), Ovarian Cancer (OVCAR-8), Renal Cancer (786–0, A498, CAKI-1, RXF 393 andTK-10) and Breast Cancer (MDA-MB-231/ATCC, HS 578 T and MDA-MB-468). On the other hand, while, compound 5d showed weak to moderate cytostatic activity towards CNS Cancer (SF-268 and SNB-19), and Breast Cancer (BT-549) with TGI = 56.8, 16.2 and 33.7 µM, respectively, it proved to have no cytostatic impact (TGI >100 µM) against entire Leukaemia, Colon cancer and Prostate Cancer and the remaining examined cancer cell lines (Table 2). Furthermore, compound 5d as revealed by the results could be considered as a non-lethal agent that exhibited LC50 values more than 100 µM for the all of cancer cell lines herein examined, except for three cancer cell lines; Non-Small Cell Lung Cancer (HOP-62), CNS Cancer (SNB-75) and Melanoma (MASK-MEL-2) which possessed a lethal effect of IC50 = 8.44, 6.04 and 54.7, respectively (Table 2).

On the other hand, as shown in Table 3, all tested subpanels were sensitive to compound 5d with MG-MID spinning between 1.92 and 3.18 µM and the most susceptible subpanels were Colon Cancer and Renal Cancer that exhibited MG-MID = 1.92 and 1.98 µM, respectively. Furthermore, it is well known that compounds with selectivity index between 3 and 6 are considered to be of a moderate selectivity, ratios more than six indicated high selectivity towards the corresponding cell line, while compounds not meeting either of these values are considered as non-selective. Therefore, as displayed in the Table 3, the calculated selectivity index for compound 5d ranged from 0.78 to 1.30 indicated that conjugate 5d has non-selective, broad spectrum antiproliferative activity against all tested subpanels cancer cells.

In vitro anti-cancer activity against SW-620 and HT-29colorectal cancer cell lines

In the present investigation a new set of benzofuran–isatin hybrids (5a–e and 7a–i) was synthesised to be evaluated for their potential anticancer activity towards two human colorectal cancer cell lines, SW-620 and HT-29. The anticancer activity of the new conjugates was assessed using MTT assay, and the results were shown in Figure 3. The most active compound in the NCI assay (5d), in addition to another one from untested compounds by NCI (5a), were selected to explore their activity. Both, SW-620 and HT-29 cells were treated with 10 µM of each compound for 24 h and the percent cell viability was calculated using MTT assay. Regarding impact of the target conjugates towards SW-620 cancer cells viability, compound 5d exhibited about 52% inhibition, whereas, compound 5a showed 46% inhibition. On the other hand, the results showed that seven compounds (5a, 5d, 7b, 7c, 7e, 7h and 7i) showed >50% inhibition of HT-29 cancer cells viability (Figure 3).

Figure 3.

Effect of benzofuran–isatin conjugates (5a–e and 7a–i) on the cell viability. (A) SW-620 with hybrids 5a–e and 7a–i, (B) HT-29 with hybrids 5a–e and 7a–i.

The results revealed that compounds 5a and 5d exhibited promising cytotoxic activity for both cell lines. For this reason, compounds 5a and 5d were pursued for further studies. Starting with determination of IC50s and cytotoxic selectivity studies. Serial concentrations of compounds 5a and 5d were used to examine their impact on cell viability using MTT protocol. Results of concentration vs percent viability were charted, and the IC50 was calculated for SW-620 and HT-29 cell lines using Graph Pad prism 8 (Figure 4). Compound 5a was found to have IC50 = 9.4 µM and 8.7 µM against SW-620 and HT-29 cell lines, respectively. In addition, the IC50 for compound 5d equals 9.8 µM and 6.5 µM against SW-620 and HT-29 cell lines, respectively, compared to IC50 of Irinotecan, a reference drug, which was found to be 1.0 µM against SW-620 cell line and 6.18 µM against HT-29 cell line (Figure 4).

Figure 4.

IC50 of Compound 5a and 5d. (A) SW-620 with compound 5a, (B) HT-29 with 5a, (C) SW-620 with compound 5d, and (D) HT-29 with 5d.

Furthermore, selective cytotoxicity of compounds 5a and 5d was studied on human skin fibroblast (HFF-1) normal cells. Both conjugates were found to possess a little effect on fibroblast normal cell viability (Figure 5). These results revealed that compounds 5a and 5d possessed a selective cytotoxicity against SW-620 and HT-29 cancer cell lines with non-significant effect on normal fibroblast cells.

Figure 5.

Impact of 5a and 5d on normal HFF-1 fibroblast cells, upon incubation for 24 h. (A) compound 5a and (B) compound 5d.

Annexin V-FITC/propidium iodide apoptosis assay

Further investigation for compounds 5a and 5d concerning their potential role of apoptosis induction, using Annexin V-FITC/PI double staining assay, was performed to evaluate their impact on both early and late apoptosis percentages in SW-620 cancer cell lines (Figure 6). The assay findings showed that compounds 5a and 5d resulted in a dose dependent induction of apoptosis for SW-620 cancer cells. As shown, compound 5a induced approximately 1.7-folds and 3.8-folds total increase in apoptosis at concentration of 5 µM and 10 µM, respectively, in comparison to the control untreated SW-620 cell line (Figure 6(A)).

Figure 6.

(A) AnnexinV/PI apoptosis assay for compound 5a. Tow concentrations (5 and 10 µM) of compound 5a, in addition untreated plate as a control were used to test the apoptotic effect by using Annexin V/PI in SW-620 cell line. Cells were treated with the compound 5a for 24 h. (B) AnnexinV/PI apoptosis assay for compound 5d. Tow concentrations (5 and 10 µM) of compound 5d, in addition untreated plate as a control were used to test the apoptotic effect by using Annexin V/PI in SW-620 cell line. Cells were treated with the compound 5d for 24 h.

Similarly, compound 5d, at concentration of 5 µM and 10 µM approximately induced 2.9-folds and 3.8-folds total increase in apoptosis, respectively, when incubated with SW-620 cell line, compared to the untreated cells (Figure 6(B)). Encouraged by these results compounds 5a and 5d were further investigated for their effect on the anti-apoptotic mitochondrial protein Bcl2 and their effect on the level of cleaved PARP in SW-620 colorectal cancer cell line.

Effect of compounds 5a and 5d on the anti-apoptotic markers Bcl2 and the level of cleaved PARP

To further examine the possible mechanism of apoptosis, the effect of compounds 5a and 5d on certain apoptosis-related proteins was studied. Bcl2 protein as a critical component of the mitochondrial apoptotic pathway is reported to be overexpressed in numerous tumours causing survival of cancer cell. In addition, it was reported that caspase activation during apoptosis leads to proteolytic cleavage of several cellular substrates participating in DNA reparation including [poly (ADP-ribose) polymerase]. Therefore, the impact of compounds 5a and 5d on the anti-apoptotic protein Bcl2 and the level of cleaved PARP was examined (Figure 7). The results showed that, Western blot analysis of the extracts prepared from SW-620 cells incubated with compound 5a (5 μM and 10 μM) for 24 h, resulted in a dose dependent inhibition of Bcl2 protein expression and significant increase in the level of cleaved PARP (Figure 7(A)).

Figure 7.

(A) Effect of hybrid 5a on anti-apoptotic Bcl2 protein and the level of cleaved PARP. Statistical analysis was performed where the significance of data was assessed at a p values < 0.05. *** p < 0.001; ** p < 0.01 control vs treated. (B) Effect of hybrid 5d on anti-apoptotic Bcl2 protein and the level of cleaved PARP. Statistical analysis was performed where the significance of data was assessed at a p values < 0.05. *** p < 0.001; ** p < 0.01 control vs treated.

Similarly, compound 5d was found to follow the same pattern with significant inhibition of the anti-apoptotic Bcl2 protein expression and significant increase in the level of cleaved PARP in SW-620 cancer cells (Figure 7(B)). These findings indicated that both compounds 5a and 5d inhibited SW-620 cells viability by deregulating apoptosis-related proteins (anti-apoptotic Bcl2 and cleaved PARP) resulting in the induction of apoptosis.

Conclusions

In summary, a novel series of benzofuran-isatin conjugates linked by a carbohydrazide group, (5a–e and 7a–i) was designed and synthesised. Seven compounds (5b–d and 7a,b,d,g) were selected according to NCI’s DTP selection guidelines for the assessment of their antitumor activity against NCI-55 human cancer cell lines. All compounds proved effective against diverse cell lines among which compound 5d was promoted to the five-dose screen and showed good to excellent growth inhibitory activity against almost all subpanel cancer cell lines. In addition, the novel conjugates (5a–e and 7a–i) showed good anti-proliferative activity against two human colorectal cancer cell lines, SW-620 and HT-29, with excellent inhibitory activity for compounds 5a and 5d that showed IC50 = 8.7 µM and 9.4 µM for 5a and IC50 = 6.5 µM and 9.8 µM for 5d against SW-620 and HT-29 cell lines, respectively, and proved to have selective cytotoxicity with increased safety profile to fibroblast (HFF-1) normal cells. Further mechanistic studies revealed that both compounds 5a and 5d were able to induce apoptosis in a dose dependent manner with an approximately 1.7–3.8 folds and 2.9–3.8 folds total increase in apoptosis for compounds 5a and 5d, respectively, compared to the control untreated SW-620 cell line. Furthermore, both conjugates significantly inhibited the expression of the anti-apoptotic Bcl2 protein and increased the level of the cleaved PARP and resulted in SW-620 cells apoptosis. Collectively, the significant potency and high selective cytotoxicity of this series specially compounds 5a and 5d suggested that these conjugates might serve as starting point for additional optimisation to develop potential anticancer agents and apoptotic inducers.

Experimental

General

Solvents of HPLC grade have been used and purchased from Thermo Fisher. Follow up of reactions has been performed utilising precoated TLC F254 Merck plates. Schimadzu FT-IR spectrometer has been used for functional groups analysis for the synthesised derivatives. NMR spectrometric analyses have been conducted using Bruker-Avance 400 NMR spectrometer (100 MHz for 13CNMR and 400 MHz for 1H NMR). Chemical shifts have been recorded in ppm. Multiplicities have been reported with their 1st order J coupling constants (Hz) for doublets (d); Stuart apparatus has been used to determine the melting points. FLASH 2000 CHNS/O analyser has been adopted to perform the elemental analysis. Compounds 3, and 6a–i, have been reported previously.

Synthesis of target derivatives 5a–e and 7a–i

To stirred hot solution of 3-methylbenzofuran-2-carbohydrazide 3 (0.25 g, 1.3 mmol) in 13 ml of absolute EtOH with catalytic drops of ethanoic acid, equivalent amount of appropriate indoline-2,3-dione compounds 4a–e or 6a–i has been added. The reaction mixture has been then refluxed for (3–6) h. The produced precipitate, after cooling, was collected by filtration, washed with water then recrystallized from glacial acetic acid to produce target derivatives 5a–e and 7a–i, respectively in a good yield (70–87%).

Full characterisation (NMR, IR, and elemental analysis) data for target compounds (5a–e and 7a–i) have been presented in the Supporting Materials.

All in vitro biological assays in this study; NCI anticancer screening,, MTT cell viability assay, Annexin V-FITC/PI assay and Western blot analysis were performed as reported earlier. All experimental procedures were provided in the Supporting materials.

Click here for additional data file.